The role of depression in the prediction of a “late” remission in first-episode psychosis: An analysis of the OPTiMiSE study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The role of depression in the prediction of a “late” remission in first-episode psychosis : An analysis of the OPTiMiSE study. / Fraguas, David; Díaz-Caneja, Covadonga M.; Pina-Camacho, Laura; Winter van Rossum, Inge; Baandrup, Lone; Sommer, Iris E.; Glenthøj, Birte; Kahn, René S.; Leucht, Stefan; Arango, Celso.
I: Schizophrenia Research, Bind 231, 2021, s. 100-107.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The role of depression in the prediction of a “late” remission in first-episode psychosis
T2 - An analysis of the OPTiMiSE study
AU - Fraguas, David
AU - Díaz-Caneja, Covadonga M.
AU - Pina-Camacho, Laura
AU - Winter van Rossum, Inge
AU - Baandrup, Lone
AU - Sommer, Iris E.
AU - Glenthøj, Birte
AU - Kahn, René S.
AU - Leucht, Stefan
AU - Arango, Celso
N1 - Publisher Copyright: © 2021
PY - 2021
Y1 - 2021
N2 - Objective: The identification of predictors of psychosis remission could guide early clinical decision-making for treatment of first-episode schizophrenia (FES). Methods: We analyzed two non-independent subsamples of patients with FES ages 18–40 years from the OPTiMiSE study dataset to investigate the demographic and clinical factors that might help to differentiate “late” remitters (i.e., not in remission at week 2 or 4, but achieving remission within a 10-week follow-up period) from non-remitters within the same period. Results: Subsample 1 included 216 individuals (55 females, mean age 25.9 years) treated with amisulpride in an open-label design who were not in remission at week 2. Early symptomatic response between baseline and week 2 (odds ratio (OR) = 4.186, 95% confidence interval (CI) = 2.082–8.416, p < 0.001) and older age (OR = 1.081, 95% CI = 1.026–1.138, p = 0.003) were the only variables significantly associated with a higher probability of psychosis remission at week 4. Subsample 2 was composed of the 72 participants (19 females, mean age 25.1 years) who were not in remission at week 4 and completed a 6-week double-blind randomized trial comparing continuation of amisulpride with switch to olanzapine. Depression at baseline (as measured with the Calgary Depression Scale for Schizophrenia) was significantly associated with a nearly 3-fold lower likelihood of psychosis remission during the 10-week follow-up (hazard ratio = 2.865, 95% CI = 1.187–6.916, p = 0.019). Conclusion: Our results reinforce the importance of assessing depressive symptoms in people with FES and support the relevance of an early response (as early as 2 weeks) as a predictor of clinical outcome in this population. Clinical trials registration: ClinicalTrials.gov identifier: NCT01248195, https://clinicaltrials.gov/ct2/show/NCT01248195.
AB - Objective: The identification of predictors of psychosis remission could guide early clinical decision-making for treatment of first-episode schizophrenia (FES). Methods: We analyzed two non-independent subsamples of patients with FES ages 18–40 years from the OPTiMiSE study dataset to investigate the demographic and clinical factors that might help to differentiate “late” remitters (i.e., not in remission at week 2 or 4, but achieving remission within a 10-week follow-up period) from non-remitters within the same period. Results: Subsample 1 included 216 individuals (55 females, mean age 25.9 years) treated with amisulpride in an open-label design who were not in remission at week 2. Early symptomatic response between baseline and week 2 (odds ratio (OR) = 4.186, 95% confidence interval (CI) = 2.082–8.416, p < 0.001) and older age (OR = 1.081, 95% CI = 1.026–1.138, p = 0.003) were the only variables significantly associated with a higher probability of psychosis remission at week 4. Subsample 2 was composed of the 72 participants (19 females, mean age 25.1 years) who were not in remission at week 4 and completed a 6-week double-blind randomized trial comparing continuation of amisulpride with switch to olanzapine. Depression at baseline (as measured with the Calgary Depression Scale for Schizophrenia) was significantly associated with a nearly 3-fold lower likelihood of psychosis remission during the 10-week follow-up (hazard ratio = 2.865, 95% CI = 1.187–6.916, p = 0.019). Conclusion: Our results reinforce the importance of assessing depressive symptoms in people with FES and support the relevance of an early response (as early as 2 weeks) as a predictor of clinical outcome in this population. Clinical trials registration: ClinicalTrials.gov identifier: NCT01248195, https://clinicaltrials.gov/ct2/show/NCT01248195.
KW - Antipsychotic
KW - Depression
KW - Remission
KW - Response
KW - Schizophrenia
U2 - 10.1016/j.schres.2021.03.010
DO - 10.1016/j.schres.2021.03.010
M3 - Journal article
C2 - 33838518
AN - SCOPUS:85103937241
VL - 231
SP - 100
EP - 107
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
ER -
ID: 276331884